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Abstract 
Background: In the United States, over 1,650,000 new cases of cancer are being diagnosed yearly with almost 50 % 
of them being the top five bone-seeking cancers. Since cancer risk increases with age, this suggests that orthopedic 
oncology services may be a strain on the Medicare system. The femur is the most common site of long bone metasta-
ses. Prophylactic fixation techniques prevent pathologic fractures, reduce morbidities, and enhance the quality of life 
of patients with femoral metastases. This study aims to assess the rate of metastatic disease to the skeleton and evalu-
ate the use and financial burden of femoral prophylactic fixation techniques on the Medicare system.
Questions/purposes: (1) In the Medicare population, has the number of skeletal metastases increased? (2) In the 
Medicare population, has the use of prophylactic fixation techniques increased? (3) How has the financial burden of 
prophylactic fixation changed over the study period?
Methods: The Medicare database was searched between 2005 and 2014 with the assistance of PearlDiver Technolo-
gies Inc. and the RBRVS DataManager Online from the American Medical Association. Searches were completed by 
using International Classification of Disease-9 (ICD-9) and current procedural terminology (CPT) codes for secondary 
malignant neoplasms and prophylactic fixation techniques. Facility charges, Medicare reimbursement and length of 
hospital stay were extracted from the Medicare database. Simple linear regression was performed to test the signifi-
cance of yearly changes and the coefficient of determination was used to assess the strength of the correlation.
Results: (1) In the Medicare population, has the number of skeletal metastases increased? While the number of 
Medicare patients with skeletal metastases has increased from 132,452 in 2005 to 155,819 in 2012 (p = 0.01, r2 = 0.72), 
the prevalence of skeletal metastases in this population remained constant at 30.66 cases per 10,000 Medicare patients 
in 2012 (p = 0.56, r2 = 0.06). (2) In the Medicare population, has the use of prophylactic fixation techniques increased? 
The number of prophylactic fixation techniques has not increased from 2005 to 2014 (p = 0.68, r2 = 0.02); however, 
the rate of prophylactic fixation among those diagnosed with skeletal metastases has significantly decreased from 94.6 
per 10,000 in 2005 to 82.72 per 10,000 in 2012 (p = 0.006, r2 = 0.74). (3) How has the financial burden of prophylactic 
fixation changed over the study period? Both total and average hospital charges increased after adjusting for inflation 
in the total Medicare population; however, only the average Medicare reimbursement changed to reflect this. The total 
amount Medicare spent on prophylactic fixation techniques in 2012 was $20,245,957 after adjusting to 2014. Despite 
the increase in hospital charges and average Medicare reimbursement, the average length of hospital stay in the 
total Medicare population showed a significant decreased trend—down from 7.51 days in 2005 to 5.86 days in 2012 
(p = 0.02, r2 = 0.81).
Conclusions: Although the prevalence of metastatic disease to the skeleton remained stable between 2005 and 
2012 in the Medicare population, prophylactic femoral fixation techniques declined in elderly adults between 2005 
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Introduction
Background
In the United States, over 1,650,000 new cases of can-
cer are diagnosed every year and almost 50  % of these 
cases are the top five bone-seeking cancers: multiple 
myeloma, breast, lung, prostate and kidney (American 
Cancer Society 2012; Kelly et al. 2012). As a group, these 
cancers have shown an increase in the number of cases 
diagnosed each year for at least the past decade (Ameri-
can Cancer Society 2005, 2006, 2007, 2008, 2009, 2010, 
2011, 2012). Of cancers that metastasize to the skeleton, 
the most common site in long bones is the femur (Hat-
tori et  al. 2007; Toliusis et  al. 2010). Metastatic disease 
of the femur is associated with severe pain, functional 
decline, and pathologic fracture, which can lead to a sig-
nificantly worse quality of life and a state of dependency 
(Bickels et al. 2009). Given the devastating consequences 
of pathologic femur fractures, orthopedic oncologists 
use prophylactic fixation techniques to improve their 
patients’ pain, mobility, and quality of life (Alvi and Dam-
ron 2013; Arvinius et  al. 2014; Bickels et  al. 2009; Gar-
trell and Saad 2014; Haidukewych 2012; Hattori et  al. 
2007; Miller et al. 2011; Moon et al. 2014; Ristevski et al. 
2009; Toliusis et  al. 2010). Other benefits of prophylac-
tic fixation of an impending fracture include decreased 
hospital stay, earlier return to ambulation, and improved 
survival (Arvinius et al. 2014; Haidukewych 2012; Riste-
vski et al. 2009; Toliusis et al. 2010). Intramedullary nails 
and cephalomedullary nails are widely used as means 
to treat impending pathologic fractures. These fixation 
methods aim to maximize the remaining quality of life as 
over 60 % of patients with metastatic disease of the femur 
that require intervention are likely to die within the year 
(Miller et al. 2011; Ristevski et al. 2009).
Rationale
Since cancer diagnoses increase with age, this suggests 
that the amount of orthopedic oncology services and 
their associated costs could be a strain on the Medicare 
system. Given the potentially high demand for these 
orthopedic procedures to treat metastatic disease of 
the femur, this study aims to assess the patient load and 
financial burden associated with prophylactic fixation 
within the Medicare inpatient population from 2005 to 
2014. We hypothesize that, as a product of the increasing 
burden of metastatic disease, there has been an increase 
in the utilization of prophylactic fixation and associated 
healthcare costs.
Study questions
1. In the Medicare population, has the number of skel-
etal metastases increased?
2. In the Medicare population, has the use of prophy-
lactic fixation techniques increased?
3. How has the financial burden of prophylactic fixation 
changed over the study period?
Methods
Study design and setting
This is a retrospective, cross-sectional study of the Medi-
care database between 2005 and 2014.
Participants/study subjects
This study looked at the Medicare inpatient database 
from 2005 to 2014. Medicare patients who underwent 
prophylactic fixation of the femur between 2005 and 
2012 were identified through PearlDiver Technologies 
Inc., which specializes in data retrieval for orthopedic 
patients through current procedural terminology (CPT) 
codes and International Classification of Disease-9 (ICD-
9) codes. This was the most up-to-date information that 
PearlDiver possessed due to the time it takes to compile 
the financial information. Additionally, CPT codes were 
used to search the Medicare database between 2013 
and 2014 with the Resource-Based Relative Value Scale 
(RBRVS) DataManager Online from the American Medi-
cal Association (RBRVS DataManager Online 1995).
Description of experiment, treatment or surgery
Patients in the study were identified using ICD-9 inpa-
tient procedural code 78.55, which encompasses CPT 
27187, “prophylactic treatment (nailing, pinning, plating 
or wiring) with or without methylmethacrylate, femoral 
neck and proximal femur,” and CPT27495, “prophylactic 
treatment (nailing, pinning, plating, or wiring) with or 
without methylmethacrylate, femur.” This was crossed 
with ICD-9 198.5, the code for secondary malignant neo-
plasm of the bone or bone marrow. ICD-9 198.5 was also 
run on its own by PearlDiver during this time period to 
see if the burden of metastatic disease to the skeleton has 
been increasing. Separately, CPT 27495 and 27187 were 
used to search the Medicare database between 2013 and 
and 2014. This most likely signifies an increase in other treatment modalities that can prevent pathologic fractures 
such as prophylactic hemiarthroplasty, bisphosphonates, and/or radiation therapy.
Level of evidence: Level IV, Cross-sectional Study.
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2014 through the RBRVS (RBRVS DataManager Online 
1995).
Variables, outcome measures, data sources, and bias
Prevalence was calculated using enrollment data from 
the Centers for Medicare and Medicaid Services 2013 
Statistical Supplement (Centers for Medicare and Medic-
aid Services 2013). Since this information did not include 
gender sub-groups, these were omitted when calculat-
ing prevalence. All patient information was de-identified 
by PearlDiver, so the study did not need action through 
an Institutional Review Board. Facility charges, Medi-
care reimbursement, gender, age, and length of hospi-
tal stay were extracted from the Medicare database by 
PearlDiver.
Statistical analysis, study size
Linear regression was performed to test the significance 
of yearly changes in the number of procedures, number 
of patients coded for skeletal metastases, Medicare reim-
bursement, hospital charges, and length of hospital stay. 
A significant upward trend is reported with a p value less 
than 0.05, the strength of the correlation is indicated by 
the coefficient of determination, r2, and the regression 
coefficients with their 95 % confidence intervals have also 
been calculated. All charges were adjusted for inflation to 
the year 2014 (Adjust for inflation 2014; Statistics USBoL 
2014; US Inflation Calculator 2014).
Results
(1) In the Medicare population, has the number of skeletal 
metastases increased?
The results of our search were separated into seven dif-
ferent groups based on age above or below 65 and gender. 
Patients under 65 can qualify for Medicare if they have 
been diagnosed with end stage renal disease (ESRD) or 
amyotrophic lateral sclerosis (ALS). Additionally, they 
may qualify if they have been on social security disabil-
ity income (SSDI) for 2  years (Signing up for Medicare 
2016). These patients may be able to dual qualify for both 
Medicare and Medicaid, but the data in this study only 
represents charges to the Medicare system.
The Medicare population that had been diagnosed 
with metastatic disease to the skeleton are displayed in 
Table 1 and Fig. 1. In the most recent year, there were a 
total of 155,819 patients in the Medicare system coded 
for metastatic disease to the skeleton. All seven groups 
had significant upward trends and strong correlations 
between 2005 and 2012. Additionally, the number of 
diagnoses increased by an average of 3124 (1176; 5073) 
each year during the study period. Despite this, as shown 
in Table  2, the prevalence of skeletal metastases in the 
Medicare population remained stable with a rate of 30.66 
per 10,000 (p = 0.56, r2 = 0.058) in 2012. This averaged to 
a yearly change of −0.0948 (−0.48; 0.29).
(2) In the Medicare population, has the use of prophylactic 
fixation techniques increased?
The population that underwent prophylactic fixation of 
their femurs is detailed in Table 3. A total of 1364 prophy-
lactic fixation procedures were coded for in 2014. Over-
all, there was no upward trend in the total population 
(p = 0.68, r2 = 0.02) or the over 65 age group (p = 0.11, 
r2  =  0.36). These corresponded to an average yearly 
change of 3.41 (−15.20; 22.01) and −17.50 (−40.70; 5.70), 
respectively. When further subdivided, the less than 65 
age group and the women less than 65 age group did 
show significant positive trends, (p  =  0.003, r2  =  0.80) 
and (p  =  0.001, r2  =  0.84), respectively. The yearly 
changes for these values were 6.29 (3.16; 9.41) and 5.18 
(2.89; 7.46), respectively. Table 4 and Fig. 2 show the rate 
of femoral prophylactic fixation procedures among those 
Table 1 Medicare inpatient population diagnosed with metastatic disease to the skeleton
Italic values indicate statistically significance at  p < 0.05
Year Men <65 Women <65 <65 group Men 65+ Women 65+ 65+ group Total
2005 5762 9206 14,968 64,638 52,846 117,484 132,452
2006 6008 9299 15,307 65,715 53,342 119,057 134,364
2007 6261 9540 15,801 67,650 54,047 121,697 137,498
2008 6103 9388 15,491 62,618 50,465 113,083 128,574
2009 6824 10,302 17,126 67,512 53,843 121,355 138,481
2010 7208 10,952 18,160 68,933 55,123 124,056 142,216
2011 7931 11,776 19,707 72,878 56,741 129,619 149,326
2012 8195 12,410 20,605 76,251 58,963 135,214 155,819
r2 0.93 0.89 0.91 0.68 0.57 0.64 0.72
p value 0.0001 0.0004 0.0002 0.01 0.03 0.02 0.01
Co (LCL; UCL) 360 (257; 462) 476 (312; 640) 835 (572; 1099) 1498 (479; 2517) 791 (101; 1480) 2289 (586; 3992) 3124 (1176; 5073)
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with skeletal metastases per 10,000 Medicare patients. 
There is no trend in the less than 65 age group (p = 0.60, 
r2 = 0.05), which had an average yearly change of −0.68 
(−3.69; 2.32). However, there is a significant decreased 
trend in the over 65 age group (p  =  0.004, r2  =  0.78), 
which changed by −3.05 (−4.67; −1.43) each year during 
the study period.
(3) How has the financial burden of prophylactic fixation 
changed over the study period?
The estimated total hospital charges for the Medicare 
inpatient population that had their femurs prophylacti-
cally fixated is displayed in Table 5 while the average esti-
mated hospital charge is displayed in Table 6. In 2012, the 
estimated total charge for ICD-9 78.55 was $100,951,048 
while the estimated average hospital charge was $78,317 
per case after adjusting for inflation to 2014. The upward 
trend in the total charge was significant for the total 
population with the regression coefficient indicating 
that it increased on average by $3,274,409 ($1,022,310; 
$5,526,507) each year. This significant upward trend 
was echoed in the less than 65 age groups, which is dis-
played in Fig.  3. However, it was not significant in the 
groups above the age of 65. Moreover, the estimated 
average charge for the total population was significant 
(p =  0.0007, r2 =  0.87) and increased by an average of 
$3104 ($1921; $4287) between 2005 and 2012. All groups 
were shown to have significant upward trends for aver-
age hospital charges except for the men below age 65 
(p = 0.05, r2 = 0.49).
The estimated total Medicare reimbursement for 
ICD-9 78.55 is detailed in Table 7. Overall, the Medicare 
system paid $20,245,957 for prophylactic fixation proce-
dures in 2012 after adjusting for inflation to 2014. How-
ever, there was no significant upward trend in the total 


















Fig. 1 Medicare population diagnosed with skeletal metastases
Table 2 Prevalence of skeletal metastases in the Medicare 
population per 10,000
Year <65 group 65+ group Total
2005 22.26 32.84 31.17
2006 21.80 32.78 31.00
2007 21.65 32.92 31.06
2008 20.61 29.84 28.31
2009 22.08 31.30 29.77
2010 22.61 31.30 29.84
2011 23.53 32.03 30.57
2012 23.89 32.04 30.66
r2 0.46 0.13 0.06
p value 0.065 0.39 0.56




Table 3 Medicare inpatient population that had their femurs prophylactically fixated
a Data collected from CPT codes from the Resource-Based Relative Value Scale (RBRVS) DataManager Online from the American Medical Association
Italic values indicate statistically significance at  p < 0.05
Year Men <65 Women <65 <65 group Men 65+ Women 65+ 65+ group Total
2005 47 80 127 507 619 1126 1253
2006 59 89 148 515 687 1202 1350
2007 57 91 148 538 689 1227 1375
2008 61 106 167 490 585 1075 1242
2009 57 97 154 474 651 1125 1279
2010 48 115 163 467 548 1015 1178
2011 60 106 166 478 578 1056 1222
2012 64 121 185 491 613 1104 1289
2013a – – – – – – 1372
2014a – – – – – – 1364
r2 0.20 0.84 0.80 0.42 0.29 0.36 0.02
p value 0.27 0.001 0.003 0.08 0.17 0.11 0.68
Co (LCL; UCL) 1.11 (−1.11; 
3.32)
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This is illustrated in Fig. 4. Only the combined less than 
65 age group and the women less than 65 age group 
showed significant upward trends in their estimated total 
reimbursement, (p  =  0.007, r2  =  0.73) and (p  =  0.003, 
r2  =  0.79), respectively. The estimated average Medi-
care reimbursement per case is shown in Table  8. In 
2012, the average Medicare reimbursement for the total 
population was $15,707 per case after adjusting for infla-
tion to 2014. This showed a significant positive trend 
(p =  0.04, r2 =  0.53) and the reimbursement increased 
by an average of $263 ($15; $510) per year between 2005 
and 2012 in the total population. Similarly, the women 
over 65 age group displayed a significant upward trend 
(p =  0.04, r2 =  0.53), as did the combined over 65 age 
group (p =  0.04, r2 =  0.52). However, the men over 65 
age group and the less than 65 age groups did not display 
significant trends.
Moreover, the estimated length of hospital stay for the 
Medicare inpatient population coded for ICD-9 78.55 is 
shown in Table 9. The total population showed a signifi-
cant decline in the length of hospital stay from 7.51 days 
in 2005 to 5.86 days in 2012 (p = 0.02, r2 = 0.81). This 
represents an average decline of 0.22 (0.33; 0.11) days 
each year. However, three groups did not have signifi-
cant declines in length of hospital stay: men less than 
65 (p = 0.13, r2 = 0.35), women less than 65 (p = 0.69, 
r2  =  0.03), and men over 65 (p  =  0.28, r2  =  0.19). 
Despite this, the combined less than 65 age group did 
show a significant downward trend (p = 0.02, r2 = 0.61) 




As the number of cases of bone-seeking cancers increases 
in the United States, the amount of orthopedic oncology 
services and their associated costs could be a strain on 
Table 4 Rate of prophylactic fixation in the Medicare pop-
ulation with skeletal metastases per 10,000
Italic values indicate statistically significance at  p < 0.05
Year <65 group 65+ group Total
2005 84.85 95.84 94.60
2006 96.69 100.96 100.47
2007 93.67 100.82 100.00
2008 107.80 95.06 96.60
2009 89.92 92.70 92.36
2010 89.76 81.82 82.83
2011 84.23 81.47 81.83
2012 89.78 81.65 82.72
r2 0.05 0.78 0.74
p value 0.60 0.004 0.006

























Fig. 2 Rates of prophylactic femoral fixation
Table 5 Estimated total hospital charges for the Medicare inpatient population coded for 78.55 after adjusting for infla-
tion to 2014
Italic values indicate statistically significance at  p < 0.05
Year Men <65 Women <65 <65 group Men 65+ Women 65+ 65+ group Total
2005 $3,321,798 $3,522,457 $6,844,255 $28,106,043 $33,916,448 $62,022,491 $68,866,746
2006 $3,191,238 $5,046,752 $8,237,990 $28,166,564 $36,474,070 $64,640,634 $72,878,624
2007 $3,440,358 $5,597,546 $9,037,904 $32,380,628 $39,863,264 $72,243,892 $81,281,796
2008 $4,824,453 $6,835,547 $11,660,000 $28,677,566 $33,188,385 $61,865,951 $73,525,952
2009 $4,594,260 $7,274,126 $11,868,386 $30,259,296 $39,484,025 $69,743,321 $81,611,707
2010 $4,234,515 $8,517,251 $12,751,766 $31,855,697 $37,268,545 $69,124,242 $81,876,810
2011 $4,613,752 $8,731,962 $13,345,714 $27,523,401 $40,127,393 $67,650,794 $80,996,508
2012 $5,229,775 $9,900,519 $15,130,294 $42,865,171 $42,955,385 $85,820,556 $100,951,048
r2 0.74 0.98 0.97 0.34 0.49 0.47 0.68
p value 0.006 1.76103E−6 0.00001 0.13 0.05 0.06 0.01
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the Medicare system. This study was completed to eval-
uate the burden of femoral metastases on the Medicare 
system and to analyze the associated charges.
Limitations
This study had a number of limitations. First, this is a ret-
rospective observational study that relied on the Medi-
care inpatient database. All such databases are subject 
to errors and inaccuracies in coding. For instance, while 
a prophylactic intramedullary nailing should be coded 
with 27495, it may have been miscoded with CPT 27506: 
“Open treatment of femoral shaft fracture, with or with-
out external fixation, with insertion of intramedullary 
implant, with or without curettage.” Second, the database 
was not designed to provide more specific patient infor-
mation such as age, comorbidities, preoperative diagno-
ses, or postoperative diagnoses, so this limited our ability 
to gather more detailed information on the population 
with femoral metastases.
Table 6 Estimated average hospital charge for  the Medicare inpatient population coded for  78.55 after  adjusting 
for inflation to 2014
Italic values indicate statistically significance at  p < 0.05
Year Men <65 Women <65 <65 group Men 65+ Women 65+ 65+ group Total
2005 $70,677 $44,031 $53,892 $55,436 $54,792 $55,082 $54,961
2006 $54,089 $56,705 $55,662 $54,692 $53,092 $53,778 $53,984
2007 $60,357 $61,511 $61,067 $60,187 $57,857 $58,878 $59,114
2008 $79,089 $64,486 $69,820 $58,526 $56,732 $57,550 $59,200
2009 $80,601 $74,991 $77,067 $63,838 $60,651 $61,994 $63,809
2010 $88,219 $74,063 $78,232 $68,213 $68,008 $68,103 $69,504
2011 $76,896 $82,377 $80,396 $57,580 $69,425 $64,063 $66,282
2012 $81,715 $81,822 $81,785 $87,302 $70,074 $77,736 $78,317
r2 0.49 0.94 0.93 0.53 0.89 0.80 0.87
p value 0.05 0.00009 0.00009 0.04 0.0004 0.003 0.0007

















Fig. 3 Estimated total hospital charges
Table 7 Estimated total Medicare reimbursement for the Medicare inpatient population coded for 78.55 after adjusting 
for inflation to 2014
Italic values indicate statistically significance at  p < 0.05
Year Men <65 Women <65 <65 group Men 65+ Women 65+ 65+ group Total
2005 $721,491 $995,625 $1,717,115 $6,864,726 $8,274,647 $15,139,373 $16,856,488
2006 $973,424 $1,231,249 $2,204,673 $6,811,380 $9,572,709 $16,384,089 $18,588,762
2007 $804,462 $1,245,873 $2,050,335 $7,364,483 $9,348,865 $16,713,348 $18,763,683
2008 $992,739 $1,466,225 $2,458,964 $7,257,886 $8,118,277 $15,376,163 $17,835,127
2009 $1,067,505 $1,741,063 $2,808,569 $7,119,188 $9,660,526 $16,779,715 $19,588,283
2010 $777,511 $1,717,583 $2,495,094 $7,194,923 $8,308,407 $15,503,330 $17,998,424
2011 $989,193 $1,475,928 $2,465,122 $6,372,876 $8,091,785 $14,464,661 $16,929,783
2012 $1,070,240 $2,013,565 $3,083,805 $8,045,193 $9,116,958 $17,162,151 $20,245,957
r2 0.29 0.79 0.73 0.11 0.02 0.005 0.13,
p value 0.17 0.003 0.007 0.43 0.75 0.87 0.38,
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Third, no ICD-9 code that is specific to metastatic dis-
ease of the femur exists, so the best surrogate marker 
was ICD-9 code 198.5—secondary malignant neoplasm 
of bone or bone marrow. Due to this, we had no way of 
knowing the percentage of patients with metastatic dis-
ease of the femur that did not undergo prophylactic sur-
gical management. However, it is reasonable to assume 
that the percentage is increasing in the over 65 age groups 
since the utilization of prophylactic fixation techniques 
has not increased, but the number of cases of metastatic 
disease to the skeleton has increased. Fourth, ICD-9 code 
78.55 encompasses prophylactic fixation techniques for 
metastatic disease to the femur, so we were unable to 
study trends in specific procedures. While more specific 
CPT codes do exist, these are not used for coding the 
inpatient Medicare population in the PearlDiver data-
base. Additionally, the data that PearlDiver has available 
is a couple of years behind the current date because of all 
the data they compile. In order to get more current infor-
mation, we used the RBRVS DataManager Online from 
the American Medical Association to gather data on pro-
phylactic femoral fixation in the years 2013–2014. Due 
to inaccuracies with coding, CPT 27495 and 27187 may 
not match the results of ICD-9 78.55 perfectly. Also, we 














Fig. 4 Total Medicare reimbursement
Table 8 Estimated average Medicare reimbursement for the Medicare inpatient population coded for 78.55 after adjust-
ing for inflation to 2014
Italic values indicate statistically significance at  p < 0.05
Year Men <65 Women <65 <65 group Men 65+ Women 65+ 65+ group Total
2005 $15,351 $12,445 $13,521 $13,540 $13,368 $13,040 $13,453
2006 $16,499 $13,834 $14,896 $13,226 $13,934 $13,219 $13,769
2007 $14,113 $13,691 $13,854 $13,689 $13,569 $13,210 $13,646
2008 $16,274 $13,832 $14,724 $14,812 $13,877 $13,872 $14,360
2009 $18,728 $17,949 $18,237 $15,019 $14,840 $14,465 $15,315
2010 $16,198 $14,936 $15,307 $15,407 $15,161 $14,813 $15,279
2011 $16,487 $13,924 $14,850 $13,332 $14,000 $13,284 $13,854
2012 $16,722 $16,641 $16,669 $16,385 $14,873 $15,076 $15,707
r2 0.17 0.37 0.32 0.43 0.53 0.52 0.53
p value 0.31 0.11 0.14 0.08 0.04 0.04 0.04
Co (LCL; UCL) 217 (−267; 701) 448 (−131; 1,028) 343 (−158; 843) 307 (−48; 662) 198 (12; 383) 353 (−162; 869) 263 (15; 510)
Table 9 Estimated average length of hospital stay during a prophylactic fixation procedure
Italic values indicate statistically significance at  p < 0.05
Year Men <65 Women <65 <65 group Men 65+ Women 65+ 65+ group Total
2005 9 6 7.11 7 8 7.55 7.51
2006 7 7 7 7 7 7 7
2007 7 7 7 7 7 7 7
2008 8 6 6.73 6 6 6 6.1
2009 7 6 6.37 6 6 6 6.04
2010 9 6 6.88 6 6 6 6.12
2011 6 7 6.64 6 6 6 6.09
2012 5 6 5.65 7 5 5.89 5.86
r2 0.35 0.03 0.61 0.19 0.85 0.78 0.81
p value 0.13 0.69 0.02 0.28 0.001 0.004 0.02
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did not have access to information regarding hospital 
charges, Medicare reimbursement, or length of hospital 
stay.
Moreover, during the statistical analysis, an emphasis 
on the significance of the trends was placed. This, com-
bined with multiple sub-group analyses, increased our 
chances of a false positive result.
Finally, since the data we gathered from the Medicare 
database lags by a couple of years, there is time for trends 
to change between what the database reflected and what 
is currently happening in clinical practice.
Discussion: (1) In the Medicare population, has the number 
of skeletal metastases increased?
The data we collected confirms that there is an increased 
burden of skeletal metastases in the Medicare popula-
tion since all groups showed significant upward trends 
between 2005 and 2012. While the increase in cases does 
burden the Medicare system, the prevalence of skeletal 
metastases among Medicare patients has not changed. 
This reflects the increase in cases of bone seeking can-
cers, which is what data from the American Cancer 
Society suggests (American Cancer Society 2005, 2006, 
2007, 2008, 2009, 2010, 2011, 2012). Also, the increased 
number of cases can be explained by the increase in the 
Medicare population (Centers for Medicare and Medic-
aid Services 2013).
Discussion: (2) In the Medicare population, has the use 
of prophylactic fixation techniques increased?
Utilization of prophylactic femoral fixation in adults over age 
65
With the increased cases of skeletal metastases, the 
potential need for surgical management of metastatic 
disease to the skeleton should be increasing. After focus-
ing our attention on the most common site of long bone 
metastases, we found that prophylactic fixation of the 
femur, as reported by ICD-9 inpatient procedural code 
78.55, CPT 27495, and CPT 27187, has not shown a 
significant increase in the total Medicare population 
between 2005 and 2014. Also, the largest of the Medicare 
subpopulations, adults over the age of 65, did not show 
an increasing trend between 2005 and 2012. In fact, its 
rate of use among older adults with skeletal metastases 
significantly decreased.
Since prophylactic fixation procedures have decreased 
despite the consistent prevalence of metastatic disease 
to the skeleton, then there are either fewer metastases to 
the femur, there are other CPT codes being used, or there 
are other treatment modalities that are increasingly being 
utilized to prevent impending fractures. Despite our ina-
bility to specifically study the rate of femoral metastases 
because no ICD-9 code for it exists, we believe that the 
notion that femoral metastases are decreasing can be dis-
missed. There is simply no evidence that cancer pathol-
ogy or therapy have changed in a way that would alter the 
location preference of a bone-seeking cancer.
Another possible explanation is that prophylactic fixa-
tion techniques have not increased because other pro-
cedures are being used to stabilize impending fractures. 
The use of CPT code 27125, “hemiarthroplasty, hip, par-
tial (e.g., femoral stem prosthesis, bipolar arthroplasty)” 
could explain why prophylactic fixation techniques have 
not become more common. Studying the rate of CPT 
27125 could be an avenue of future research; however, 
it may be difficult to know whether the procedures were 
done prophylactically since it is not specified in the code 
and no prophylactic hemiarthroplasty code exists.
The third explanation, other treatment modalities are 
stabilizing femoral metastases, is the most plausible. In 
particular, radiotherapy and osteoclast inhibiting medi-
cations have been used to treat metastatic disease to the 
femur (Bickels et al. 2009). Radiation has been effective 
for pain management in those with metastatic femoral 
lesions and was shown to circumvent the need for surgi-
cal intervention in 81 % of impending fracture cases in 
one study (Harada et al. 2010). Other benefits of using 
radiation therapy over surgery include decreased pain, 
risk of DVT, fat embolism, anesthesia risk, and hospital 
stay (Hattori et al. 2007; Kelly et al. 2012; Swanson et al. 
2000). Additionally, using radiotherapy instead of sur-
gery may be more cost effective than prophylactic fixa-
tion and further studies would be required to evaluate 
this.
Another non-surgical treatment is the use of bispho-
sphonates or RANKL inhibitors, which prevent osteo-
clasts from resorbing bone. They have both been shown 
to decrease the number of bony metastases, decrease the 
prevalence of pathologic fractures, and prevent the need 
for surgical fixation (Bickels et al. 2009; Gartrell and Saad 
2014; Saad et al. 2002). While both bisphosphonates and 
RANKL inhibitors are effective, a recent meta analysis 
has shown that RANKL inhibitors are better at prevent-
ing pathologic fractures than bisphosphonates (Lipton 
et al. 2012). The increased use of these medications may 
be circumventing the need for prophylactic fixation. 
Again, comparing the costs of this therapy with the costs 
of prophylactic fixation could be a future area of research 
to determine the most effective use of resources.
Despite a possible increase in the utilization of other 
treatment modalities, the benefits of early prophylac-
tic fixation have recently been re-emphasized in the lit-
erature. One study did so by comparing prophylactic 
intramedullary nailing outcomes with the outcomes 
of therapeutic intramedullary nailing after a patho-
logic fracture. Significant benefits supporting the use 
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of prophylactic nailing included shorter hospital stay, 
earlier weight bearing, and increased survival (Arvinius 
et al. 2014). Also, it is important to note that the major-
ity of pathologic fractures never heal, especially if they 
have previously received radiation therapy (Haidukew-
ych 2012; Miller et al. 2011). This could adversely affect 
ambulation and put the hardware at a higher risk of 
failure.
Additionally, prophylactic intramedullary nails have 
been shown to have a low failure rate, 11  %, and a low 
complication rate, 12.5 %, which support their continued 
use (Alvi and Damron 2013). This has led to the conclu-
sion that it is appropriate to protect the entire length of 
the bone in case of disease progression. However, one 
study suggests that it is unnecessary to routinely protect 
the femoral neck since none of their 145 study partici-
pants developed metastases in that region (Moon et  al. 
2014).
Utilization of prophylactic femoral fixation in the under age 
65 population
The two groups that did show significant upward trends 
in the use of prophylactic fixation techniques were total 
adults under the age of 65 and women under the age of 
65. Since men under the age of 65 did not show a signifi-
cant trend, it is likely that the women in the total popula-
tion under 65 were the driving force for its significance.
Despite the increase in the number of prophylactic 
fixation procedures, the rate of their use among those 
with skeletal metastases did not change in the less than 
65 group. It stayed consistent with the prevalence of 
skeletal metastases. This contrasts with the older popu-
lation, which saw a decreased trend in the context of an 
unchanging prevalence.
There has been some evidence that younger women, 
particularly those less than age 35, have worse breast 
cancer prognoses (Fredholm et al. 2009; Liu et al. 2015). 
Since they have more aggressive tumors, perhaps they 
did not respond well enough to radiotherapy or osteo-
clast inhibitors and required surgical fixation more often. 
Also, since they were younger, surgery may have been 
used more readily since their potential for survival may 
have been greater or overestimated.
Discussion: (3) How has the financial burden 
of prophylactic fixation changed over the study period?
Increasing total hospital charges in the under 65 age group
When looking at the estimated total charges, both 
the overall population’s total hospital charges and the 
less than 65 age groups had significant upward trends. 
Because the over 65 age groups did not have significant 
trends, it is likely that the under 65 age groups were the 
drivers of the total group’s trend.
A possible explanation for why the younger groups had 
higher hospital charges could be that those who qualify 
for Medicare under the age of 65 have significant comor-
bidities that could be increasing their cost of care.
Significant increase in average hospital charges, but not total 
hospital charges
All groups except for men under age 65 showed a sig-
nificant upward trend in the average hospital charges for 
ICD-9 78.55. It seems contradictory that the total hospi-
tal charge for the over 65 age group was not statistically 
significant, but the average hospital charge was statisti-
cally significant. An explanation for this is that the num-
ber of procedures has not increased, but the cost per 
procedure has. This would reflect a higher average hos-
pital charge that may not be reflected in the total hospital 
charge.
This requires an explanation of why the average charge 
is increasing after adjusting for inflation. Since there are 
other treatment modalities in place to treat metastatic 
disease of the femur, surgery may be seen as more of a 
final effort to prevent a pathologic fracture. Studies on 
some surgical procedures, such as pancreaticoduodenec-
tomy, have shown that a decreased volume of procedures 
can lead to an increase in its cost (Sutton et al. 2014). The 
decreased use of ICD-9 78.55 could therefore be increas-
ing its value.
While this explanation holds true for the above 65 age 
groups since they did not have an increase in prophylac-
tic fixation, the less than 65 age group and the women 
less than 65 age group did have a significant upward 
trend in prophylactic fixation, so the explanation of fewer 
procedures yields a higher cost does not apply here. 
As mentioned previously, the less than age 65 popula-
tion may have significant comorbidities, which allowed 
them to enroll in Medicare. The management of those 
conditions could also be contributing to their increased 
average hospital charge. For instance, ESRD is one condi-
tion that qualifies the under 65 age group for Medicare. 
Hemodialysis is known to be an expensive procedure and 
if the patient required dialysis during their hospitaliza-
tion for prophylactic femoral fixation then this would 
increase the hospital charge during their stay.
Medicare reimbursement rates
When looking at the total Medicare inpatient reimburse-
ments, only the less than 65 combined age group and 
the women less than 65 age group showed a significant 
increasing trend. This reflects the increasing total hospital 
charges for these groups. Although the men less than 65 
age group and the total Medicare inpatient group showed 
significantly increasing total hospital charges, this was 
not reflected in their total Medicare reimbursement. The 
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reasons for how Medicare decides their reimbursement 
rate is beyond the scope of this paper, but our data sug-
gests that it is not solely a proportion of the amount the 
hospitals decide to charge.
Lastly, the average Medicare reimbursement for ICD-9 
78.55 showed a significant upward trend in the women 
over 65 age group, the combined over 65 age group, and 
the total Medicare inpatient population. However, all of 
the significant values were on the lower ends of what is 
considered a strong correlation and the combined over 
65 age group and the total group likely owe their signifi-
cance to the women over 65 age group. Despite showing 
a significant increased trend in average hospital charge, 
the women less than 65 age group, the combined less 
than 65 age group, and the men over 65 age group did not 
have a significant positive trend in their average Medi-
care reimbursement. Again, this suggests that Medicare 
reimbursement is not simply a proportion of what the 
hospitals charge.
Length of hospital stay
Even though total and average hospital charges have 
increased in the total Medicare population, both the over 
and under 65 year old combined groups, the women over 
65 age group, and the total population group showed a 
significant decreased trend in the average hospital stay. 
However, since both the men less than 65 and the women 
less than 65 groups did not show a significant decreased 
trend, it is possible that the significant trend in the com-
bined less than 65 group is an artifact. The women less 
than 65 group essentially shows no change in their aver-
age hospital stay while the men less than 65 start high at 
9  days then drop down to only 6 and 5  days in the last 
2  years. This decrease in the last 2  years happened too 
late in the study period to affect the overall trend in this 
group, but when averaged with the women under 65 in 
the combined less than 65 age group, it was able to form 
a trend.
With regard to the over 65 age group, the decreased 
trend in average hospital stay was likely driven by the 
women over 65 group. Since the population in this group 
was so large, it may have also driven the decreased trend 
in the total group as well.
Conclusions
The benefits of prophylactically fixating femoral metas-
tases are well documented and, since the number of 
bone-seeking cancers is on the rise in the US, the finan-
cial burden that a high volume of the procedure places 
on the Medicare system could be staggering. This study 
confirms the increased burden of metastatic disease to 
the skeleton in all of our Medicare subpopulations even 
though its prevalence remained stable. Despite this, 
the rate of prophylactic fixation techniques decreased 
between 2005 and 2012 in the largest Medicare subpopu-
lation, adults over 65. This may reflect the increased uti-
lization of prophylactic hemiarthroplasty or non-surgical 
therapy. Future studies comparing ICD-9 inpatient pro-
cedural code 78.55 to these therapies would need to be 
conducted to affirm this.
Although adults over 65 have not shown an increase in 
prophylactic femoral fixation procedures, women under 
65 did have a significant increased trend and a consistent 
rate. This may be due to the presence of more aggressive 
breast cancers in younger women that do not respond 
to non-surgical therapy and an increased readiness of 
clinicians to recommend surgical fixation to a younger 
population.
From a financial perspective, Medicare spent 
$20,245,957 in 2012 on reimbursements for ICD-9 inpa-
tient procedural code 78.55 after adjusting for inflation 
to 2014. While this is widely considered to be a cost-
saving procedure, future studies should compare the cost 
effectiveness of it with the treatment modalities that are 
potentially replacing it. Depending on how many of those 
treatments fail and eventually require prophylactic fixa-
tion, the use of ICD-9 78.55 from the beginning may be 
the most cost-effective approach.
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